德适生物港股上市获证监会备案通过

Group 1 - The China Securities Regulatory Commission has issued a notice regarding Hangzhou Deshi Biotechnology Co., Ltd.'s overseas issuance and domestic unlisted shares "full circulation" filing, with plans to issue no more than 31,004,000 overseas listed common shares and list on the Hong Kong Stock Exchange [1][3] - Deshi Biotechnology, founded in 2016, is a leading company in the field of medical imaging AI and intelligent equipment, with significant growth expected in its bidding quantity and amount for 2025 compared to 2024, indicating strong annual performance growth [1][3] - As a national "specialized and innovative" small giant enterprise, Deshi Biotechnology has invested over 100 million yuan in AI research and development, computing power, and intelligent manufacturing, further solidifying its competitiveness in the medical imaging AI and intelligent equipment sector [1][3] Group 2 - According to NVIDIA's forecast, the global medical imaging intelligence market is expected to exceed 100 billion USD by 2030 [2][4] - The National Health Commission and other departments have issued implementation opinions to promote and standardize the application of "AI + healthcare," aiming for basic coverage of intelligent auxiliary applications in grassroots diagnosis and treatment by 2030, with a push for secondary hospitals to widely adopt AI technologies in medical imaging diagnosis and clinical decision-making [2][4] - Deshi Biotechnology, as an industry leader, is positioned to lead the medical imaging diagnostic industry into the intelligent era [2][4]